Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk

References

• Trepo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014;384(9959):2053–2063.
   PubMed Web of Science ®Google Scholar
• Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529–538.
   PubMed Web of Science ®Google Scholar
• Kao JH. Role of viral factors in the natural course and therapy of chronic hepatitis B. Hepatol Int. 2007;1(4):415–430.
   PubMed Web of Science ®Google Scholar
• Levrero M, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol. 2016;64(1 Suppl):S84–s101.
   PubMedGoogle Scholar
• Kim BK, Revill PA, Ahn SH. HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B. Antivir Ther. 2011;16(8):1169–1186.
   PubMed Web of Science ®Google Scholar
• Kao JH. Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol. 2002;17(6):643–650.
   PubMed Web of Science ®Google Scholar
• Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008;359(14):1486–1500.
   PubMed Web of Science ®Google Scholar
• Papatheodoridis GV, Chan HL, Hansen BE, et al. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol. 2015;62(4):956–967.
   PubMed Web of Science ®Google Scholar
• Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351(15):1521–1531.
   PubMed Web of Science ®Google Scholar
• Lin SM, Yu ML, Lee CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol. 2007;46(1):45–52.
   PubMed Web of Science ®Google Scholar
• Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381(9865):468–475.
   PubMed Web of Science ®Google Scholar
• Hosaka T, Suzuki F, Kobayashi M, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 2013;58(1):98–107.
   PubMed Web of Science ®Google Scholar
• Kim G-A, Lim Y-S, Han S, et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B. Gut. 2018;67(5):945–952.
   PubMed Web of Science ®Google Scholar
• Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1–98.
   PubMed Web of Science ®Google Scholar
• Arends P, Sonneveld MJ, Zoutendijk R, et al. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. Gut. 2015;64(8):1289–1295.
   PubMed Web of Science ®Google Scholar
• Wong GL, Chan HL, Mak CW, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology. 2013;58(5):1537–1547.
   PubMed Web of Science ®Google Scholar
• Vlachogiannakos J, Papatheodoridis G. Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. World J Gastroenterol. 2013;19(47):8822–8830.
   PubMed Web of Science ®Google Scholar
• Wong GL, Chan HL, Chan HY, et al. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. Gastroenterology. 2013;144(5):933–944.
   PubMed Web of Science ®Google Scholar
• Bekisz J, Baron S, Balinsky C, et al. Antiproliferative properties of Type I and Type II interferon. Pharmaceuticals (Basel). 2010;3(4):994–1015.
   PubMedGoogle Scholar
• Kusano H, Akiba J, Ogasawara S, et al. Pegylated interferon-alpha2a inhibits proliferation of human liver cancer cells in vitro and in vivo. PLoS One. 2013;8(12):e83195.
   PubMed Web of Science ®Google Scholar
• Liang KH, Hsu CW, Chang ML, et al. Peginterferon is superior to nucleos(t)ide analogues for prevention of hepatocellular carcinoma in chronic hepatitis B. J Infect Dis. 2016;213(6):966–974.
   PubMed Web of Science ®Google Scholar
• Li SY, Li H, Xiong YL, et al. Peginterferon is preferable to entecavir for prevention of unfavourable events in patients with HBeAg-positive chronic hepatitis B: A five-year observational cohort study. J Viral Hepat. 2017;24(Suppl 1):12–20.
   PubMedGoogle Scholar
• Kutala BK, Estrabaud E, Castelnau C, et al. Long-term risk of hepatocellular carcinoma in patients with chronic hepatitis B with normal alanine aminotransferase. SM Virology. 2016;1(2):1009.
   Google Scholar
• Kramvis A, Kew MC, Bukofzer S. Hepatitis B virus precore mutants in serum and liver of Southern African Blacks with hepatocellular carcinoma. J Hepatol. 1998;28(1):132–141.
   PubMed Web of Science ®Google Scholar
• Iloeje UH, Yang HI, Jen CL, et al. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol. 2007;5(8):921–931.
   PubMed Web of Science ®Google Scholar
• Chou YC, Yu MW, Wu CF, et al. Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma. Gut. 2008;57(1):91–97.
   PubMed Web of Science ®Google Scholar
• Wong VW, Chan SL, Mo F, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol. 2010;28(10):1660–1665.
   PubMed Web of Science ®Google Scholar
• Yuen MF, Tanaka Y, Fong DY, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol. 2009;50(1):80–88.
   PubMed Web of Science ®Google Scholar
• Yang HI, Yuen MF, Chan HL, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol. 2011;12(6):568–574.
   PubMed Web of Science ®Google Scholar
• Papatheodoridis G, Dalekos G, Sypsa V, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol. 2016;64(4):800–806.
   PubMed Web of Science ®Google Scholar
• Papatheodoridis GV, Idilman R, Dalekos GN, et al. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology. 2017;66(5):1444–1453.
   PubMed Web of Science ®Google Scholar
• Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6(3):531–561.
   PubMed Web of Science ®Google Scholar
• Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2(3):263–283.
   PubMed Web of Science ®Google Scholar
• Cho JY, Paik YH, Sohn W, et al. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease. Gut. 2014;63(12):1943–1950.
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–1022.
   PubMed Web of Science ®Google Scholar
• Kim MN, Hwang SG, Rim KS, et al. Validation of PAGE-B model in Asian chronic hepatitis B patients receiving entecavir or tenofovir. Liver Int. 2017;37(12):1788–1795.
   PubMed Web of Science ®Google Scholar
• Parsons LS Performing a 1: nCase-Control match on propensity score. the 29th Annual SAS Users Group International Conference. 2004; 165–29.
   Google Scholar
• D’Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17(19):2265–2281.
   PubMed Web of Science ®Google Scholar
• Yao GB, Zhu M, Cui ZY, et al. A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China. J Dig Dis. 2009;10(2):131–137.
   PubMed Web of Science ®Google Scholar
• Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis. 2003;36(6):687–696.
   PubMed Web of Science ®Google Scholar
• Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136(2):486–495.
   PubMed Web of Science ®Google Scholar
• Hou J, Yin YK, Xu D, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology. 2008;47(2):447–454.
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006;131(6):1743–1751.
   PubMed Web of Science ®Google Scholar
• Brechot C, Gozuacik D, Murakami Y, et al. Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Semin Cancer Biol. 2000;10(3):211–231.
   PubMed Web of Science ®Google Scholar
• Ringelhan M, O’Connor T, Protzer U, et al. The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets. J Pathol. 2015;235(2):355–367.
   PubMed Web of Science ®Google Scholar
• McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology. 2009;49(5 Suppl):S45–55.
   PubMed Web of Science ®Google Scholar
• Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337(24):1733–1745.
   PubMed Web of Science ®Google Scholar
• Chung YH, Song IH, Song BC, et al. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer. 2000;88(9):1986–1991.
   PubMed Web of Science ®Google Scholar
• Lucifora J, Xia Y, Reisinger F, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science. 2014;343(6176):1221–1228.
   PubMed Web of Science ®Google Scholar
• Belloni L, Allweiss L, Guerrieri F, et al. IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest. 2012;122(2):529–537.
   PubMed Web of Science ®Google Scholar
• Ching LK, Gounder PP, Bulkow L, et al. Incidence of hepatocellular carcinoma according to hepatitis B virus genotype in Alaska Native people. Liver Int. 2016;36(10):1507–1515.
   PubMed Web of Science ®Google Scholar
• Martinot-Peignoux M, Lapalus M, Asselah T, et al. The role of HBsAg quantification for monitoring natural history and treatment outcome. Liver Int. 2013;33 Suppl 1:125–132.
   PubMed Web of Science ®Google Scholar